This article was originally published in The Tan Sheet
Hi-Tech OTCs up slightly in fiscal 2013; Pharmstandard spins off OTC unit; Nu Skin raises estimates; infant formula makers respond to China inquiry; Pennsylvania joins NPLEx; and Everett alleges Acella infringes in prenatals.
You may also be interested in...
Rx-Only Pseudoephedrine Stalls As Meth Solution In Tennessee, Indiana
Tennessee’s meth lab seizures are up this year, but CHPA says that’s because more labs are uncovered through the state’s participation in the NPLEx stop-sale system. Rx-only bills have stalled in several states, including Indiana, where lawmakers passed a bill to cap PSE purchases at about 61 grams per year.
ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer
While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.